Sort
89,613 grants matching “depression”
Alzheimer's Gut Microbiome Project
$5,690,172Rima F Kaddurah-Daouk · Duke University · U19 · FY2019 · AG
An ultra-long-acting oral treatment for opioid use disorder
$5,658,273Patrick Boen · Lyndra Therapeutics, Inc. · UG3 · FY2019 · DA
Mount Sinai ECHO site for Perinatal Environment and Development Studies
$5,651,458Rosalind J Wright · Icahn School Of Medicine At Mount Sinai · UH3 · FY2025 · OD
Integrative genetics of behavior with high throughput technologies
$5,648,001David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2023 · AA
Integrative genetics of behavior with high throughput technologies
$5,607,530David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2025 · AA
Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder
$5,598,515John A Butera · Hager Biosciences, Llc · UF1 · FY2021 · DA
Clinical and biomarker studies in Alzheimer's disease and related disorders
$5,587,710Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2023 · AG
Engagement Core
$5,556,004Monica G Rivera-Mindt · Northern California Institute/Res/Edu · U19 · FY2025 · AG
A regulome and transcriptome atlas of fetal and adult human neurogenesis
$5,548,451Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai · RF1 · FY2021 · MH
Clinical Core
$5,500,171Ziad Nahas · University Of Minnesota · U54 · FY2022 · AT
Investigating Correlates and Therapeutics of Fatigue in Cancer Patients
$5,482,508Leorey Saligan · National Institute Of Nursing Research · ZIA · FY2022 · NR
Institutional Clinical and Translational Science Award
$5,480,123Bruce Neil Cronstein · New York University School Of Medicine · UL1 · FY2010 · RR
Improving causal inference in Alzheimer's Disease prevention research on modifiable risk factors: the Triangulation of Innovative Methods to EndAD (TIME-AD) project
$5,470,174Medellena Maria Glymour · Boston University Medical Campus · P01 · FY2025 · AG
Mount Sinai ECHO site for Perinatal Environment and Development Studies
$5,463,061Rosalind J Wright · Icahn School Of Medicine At Mount Sinai · UG3 · FY2024 · OD
Longitudinal Assessment of Post-traumatic Syndromes
$5,432,897Samuel A. McLean · Univ Of North Carolina Chapel Hill · U01 · FY2019 · MH
My Diabetes My Community
$5,427,512Elbert S. Huang · University Of Chicago · R01 · FY2020 · DK
Alzheimer's Gut Microbiome Project
$5,424,083Rima F Kaddurah-Daouk · Duke University · U19 · FY2020 · AG
CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse
$5,400,000Philip Iredale · Cerevel Therapeutics, Llc · UG3 · FY2021 · DA
R-methadone-TAAP/MPAR: an abuse deterrent methadone prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial
$5,389,398Lynn Kirkpatrick · Ensysce Biosciences, Inc. · UG3 · FY2019 · DA
SPRINT: Signature for Pain Recovery IN Teens
$5,386,781Laura E Simons · Stanford University · R61 · FY2019 · NS
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain
$5,382,096Claudia Michelle Campbell · Johns Hopkins University · UH3 · FY2021 · AR
MIND Diet Intervention to Prevent Alzheimer's Disease
$5,356,351Lisa L Barnes · Rush University Medical Center · R01 · FY2020 · AG
Centralized Sequencing Program
$5,354,569Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI
Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome
$5,353,314Kristen Leann Gullo · Uswm, Llc · UG3 · FY2021 · DA
Institutional Clinical and Translational Science Award
$5,338,922Bruce Neil Cronstein · New York University School Of Medicine · UL1 · FY2012 · TR